LionBio raises $6.0M Pre-seed (United States, Nov 2026)

$6.0M
$6 million pre-seed

Reach the investors backing rounds like this

Backed by South Park Commons · verified emails and LinkedIn on Datapile

Find your investors →
Generated social card
LionBio social card
Headline

Nasal GLP-1 startup LionBio raises $6M pre-seed - Dealroom

About

LionBio is developing nanoparticle-based GLP-1 treatments delivered through the nose, with its first candidate being a nasal formulation of semaglutide. The startup aims to expand into peptide treatments for neurological conditions and targets the olfactory epithelium for drug delivery to the brain. This pre-seed round will support its preclinical development and manufacturing scale-up.

Article summary

Nasal GLP-1 startup LionBio raises $6M pre-seed  Dealroom

Founder
Robin Guo
Robin Guo
Chief executive officer
Investors · 1
South Park CommonsLead
FUND
Related rounds
Nov 19, 2026Upwind$400.0MSeries CUnited States
Nov 19, 2026Tesorai$5.3MSeedUnited States
Nov 19, 2026Modern Industrials$6.0MSeedUnited States
Nov 19, 2026Rogo$350.0M—United States

23,886 investors back startups in United States

You just read who funded LionBio. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.

Free account: 15 investor contact unlocks a month, no card required.

About the investors in United States